Real-world study reports promising first-line orelabrutinib outcomes in CLL/SLL
A retrospective single-center study of 75 treatment-naive CLL/SLL patients reports an 86.7% response rate with frontline orelabrutinib monotherapy and no ...
A retrospective single-center study of 75 treatment-naive CLL/SLL patients reports an 86.7% response rate with frontline orelabrutinib monotherapy and no ...
A 52-week Italian real-world study of 433 patients found that upadacitinib kept moderate-to-severe atopic dermatitis in a controlled state for ...
A retrospective study of 45 hepatocellular carcinoma patients found that intratumoral tertiary lymphoid structures were associated with disease control and ...
A new spatiotemporal model estimates insecticide-treated net coverage, age and type across 44 African countries from 2006 to 2024, finding ...
New mosquito cell lines carrying five Wolbachia strains from Drosophila reveal fast, selection-driven genome evolution, including mutations linked to major ...
A phase 1 trial found that an autologous combination of natural killer cells and tumor-primed T lymphocytes was safe and ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine